Gracell Biotechnologies (NASDAQ:GRCL) Vs. ENTA, NGM, INVA, CDMO, MDGL, KROS, MOR, ADCT, PRTC, and IMGN
Should you be buying Gracell Biotechnologies stock or one of its competitors? The main competitors of Gracell Biotechnologies include Enanta Pharmaceuticals (ENTA), NGM Biopharmaceuticals (NGM), Innoviva (INVA), Avid Bioservices (CDMO), Madrigal Pharmaceuticals (MDGL), Keros Therapeutics (KROS), MorphoSys (MOR), ADC Therapeutics (ADCT), PureTech Health (PRTC), and ImmunoGen (IMGN). These companies are all part of the "pharmaceutical preparations" industry.
Gracell Biotechnologies vs.
NGM Biopharmaceuticals (NASDAQ:NGM) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
Gracell Biotechnologies has lower revenue, but higher earnings than NGM Biopharmaceuticals.
NGM Biopharmaceuticals currently has a consensus target price of $35.00, suggesting a potential upside of 140.55%. Gracell Biotechnologies has a consensus target price of $34.50, suggesting a potential upside of 698.61%. Given Gracell Biotechnologies' higher probable upside, analysts clearly believe Gracell Biotechnologies is more favorable than NGM Biopharmaceuticals.
58.5% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 48.1% of Gracell Biotechnologies shares are owned by institutional investors. 45.9% of NGM Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
NGM Biopharmaceuticals received 13 more outperform votes than Gracell Biotechnologies when rated by MarketBeat users. Likewise, 75.76% of users gave NGM Biopharmaceuticals an outperform vote while only 52.17% of users gave Gracell Biotechnologies an outperform vote.
Gracell Biotechnologies has a net margin of 0.00% compared to NGM Biopharmaceuticals' net margin of -157.90%. Gracell Biotechnologies' return on equity of 0.00% beat NGM Biopharmaceuticals' return on equity.
In the previous week, NGM Biopharmaceuticals had 2 more articles in the media than Gracell Biotechnologies. MarketBeat recorded 4 mentions for NGM Biopharmaceuticals and 2 mentions for Gracell Biotechnologies. Gracell Biotechnologies' average media sentiment score of 0.59 beat NGM Biopharmaceuticals' score of 0.09 indicating that Gracell Biotechnologies is being referred to more favorably in the news media.
Summary
NGM Biopharmaceuticals beats Gracell Biotechnologies on 9 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GRCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gracell Biotechnologies (NASDAQ:GRCL) vs. Its Competitors
Gracell Biotechnologies Competitors List
